Paid Clinical Trials Durham

Discover 1,529 paid clinical trials in Durham, North Carolina. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 1,529

A Study to Evaluate the Effect of Aficamten in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).A Study to Evaluate the Effect of Aficamten in Pediatric Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM).

Recruiting

PHASE2

PHASE3

Sponsor:

Cytokinetics

Location:

Durham NC, Washington DC, Philadelphia PA, Morristown NJshow 18 more

Code:

NCT06412666

Conditions

Pediatric

Symptomatic Obstructive Hypertrophic Cardiomyopathy

Eligibility Criteria

Sex: All

Age: 12 - 17

Healthy Volunteers: Not accepted

Interventions

Aficamten

Placebo

A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic MigraineA Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine

Recruiting

PHASE3

Sponsor:

Eli Lilly and Company

Location:

Raleigh NC, Charleston SC, Baltimore MD, Pittsburgh PAshow 41 more

Code:

NCT04616326

Conditions

Chronic Migraine

Eligibility Criteria

Sex: All

Age: 12 - 17

Healthy Volunteers: Not accepted

Interventions

Galcanezumab

Placebo

Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe DiseaseDetermination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease

Recruiting

Sponsor:

Duke University

Location:

Durham NC

Code:

NCT01665326

Conditions

Pompe Disease

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Interventions

Observational

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABGAnticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

Recruiting

PHASE3

Sponsor:

Icahn School of Medicine at Mount Sinai

Location:

Durham NC, Raleigh NC, Greenville NC, Charlottesville VAshow 45 more

Code:

NCT04045665

Conditions

Atrial Fibrillation

Stroke

Bleeding

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Antiplatelet-only strategy

Oral Anticoagulant plus background antiplatelet therapy

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

Recruiting

PHASE3

Sponsor:

Eli Lilly and Company

Location:

Raleigh NC, Greensboro NC, Fayetteville NC, Winston-Salem NCshow 172 more

Code:

NCT05026866

Conditions

Alzheimer Disease

Eligibility Criteria

Sex: All

Age: 65 - 70+

Healthy Volunteers: Not accepted

Interventions

Donanemab

Placebo

Primary Subtalar Arthrodesis for Calcaneal FracturesPrimary Subtalar Arthrodesis for Calcaneal Fractures

Recruiting

Sponsor:

Wake Forest University Health Sciences

Location:

Chapel Hill NC, Winston-Salem NC, Concord NC, Charlotte NCshow 9 more

Code:

NCT06249126

Conditions

Calcaneus Fracture

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Primary Fusion (Open Reduction Internal Fixation (ORIF) + Primary Subtalar Arthrodesis (PSTA)

Open Reduction Internal Fixation (ORIF) only

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDACA Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC

Recruiting

PHASE2

Sponsor:

Genentech, Inc.

Location:

Durham NC, Lexington KY, Cincinnati OH, Middletown NJshow 22 more

Code:

NCT05968326

Conditions

Adenocarcinoma, Pancreatic Ductal

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Autogene cevumeran

Atezolizumab

mFOLFIRINOX

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

Recruiting

PHASE3

Sponsor:

NRG Oncology

Location:

Durham NC, Chapel Hill NC, Cary NC, Raleigh NCshow 706 more

Code:

NCT05879926

Conditions

Breast Cancer

Eligibility Criteria

Sex: Female

Age: 18 - 60

Healthy Volunteers: Not accepted

Interventions

Ovarian Function Suppression + Aromatase Inhibitor

Adjuvant Chemotherapy + Ovarian Function Suppression

Prebiotic Galacto-oligosaccharide and Acute GVHDPrebiotic Galacto-oligosaccharide and Acute GVHD

Recruiting

PHASE1

PHASE2

Sponsor:

Duke University

Location:

Durham NC

Code:

NCT04373057

Conditions

Acute GVHD

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Galacto-oligosaccharide

Maltodextrin

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSELutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

Recruiting

PHASE3

Sponsor:

ITM Solucin GmbH

Location:

Durham NC, Philadelphia PA, New York NY, Tampa FLshow 9 more

Code:

NCT04919226

Conditions

Neuroendocrine Tumors

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT

CAPTEM (Capecitabine and Temozolomide)

Amino-Acid Solution

Everolimus

FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin)